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interact	with	 the	 immune	 system	 and	discuss	 how	 these	 interactions	 could	 impact	
acute	GVHD.




The	 human	 body	 is	 colonized	 by	 communities	 of	 microorganisms	
termed	the	“microbiota,”	which	include	bacteria,	fungi,	and	viruses	and	
the	gut	is	the	main	site	of	microbial	colonization.1	In	this	review	we	will	
focus	on	 the	 intestinal	microbiota.	The	 intestinal	microbiota	 is	com-
prised	of	 trillions	of	 a	diverse	 community	of	microorganisms	 largely	
consisting	of	nonpathogenic	anaerobic	commensal	bacteria.1 In recent 
years,	high	throughput	sequencing	technologies	have	made	it	possible	
to	analyze	a	large	number	of	microorganisms	in	the	gut.	Bacteroidetes	






Allogeneic	hematopoietic	cell	 transplantation	 (Allo-	HCT)	 is	a	po-
tentially	 curative	 treatment	 modality	 for	 patients	 with	 a	 variety	 of	
malignant	and	benign	hematological	diseases.	However,	the	effective-
ness	of	allo-	HCT	is	limited	by	acute	graft	versus	host	disease	(GVHD)	
which	 is	 the	principal	 cause	of	 non-	relapse	mortality.2	Conditioning	
regimens	 used	 in	 allo-	HCT	 cause	 host	 tissue	 injuries	which	 release	
“danger	 signals”	 that	activate	host	or	donor	antigen	presenting	cells	
(APCs)	 which	 in	 turn	 present	 allo-	antigens	 via	 major	 histocompati-
bility	complex	(MHC)	class	 I	or	class	 II	to	donor	T	cells.3	 In	addition,	
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verity	of	acute	GVHD.	 In	 this	 review,	we	summarize	these	data	and	























portant	 for	 intestinal	 immune	homeostasis	 and	 are	 classified	 into	3	
groups.1,5	Retinoic	acid	receptor-	related	orphan	receptor-	γt	(RORγt)+ 
group	3	innate	lymphoid	cells	(ILC3s)	regulate	commensal	bacteria	by	







free	 mice	 colonized	 with	 conventional	 intestinal	 microbiota	 devel-
oped	innate	immune	responses	and	structural	changes	with	increase	
in	 the	 depth	 of	 the	 intestinal	 epithelial	 crypts	 as	well	 as	 expansion	




(Foxp3)-	 expressing	 regulatory	 T	 cells	 (Tregs)	which	 produce	 IL-	10,	
an	 anti-	inflammatory	 cytokine.8	 In	 contrast,	 stimuli	 associated	with	
pathogenic	bacteria	cause	 inflammatory	responses	via	 IL-	1	and	 IL-	6	
induction	which	result	in	Th1	and	Th17	activation.1,5
Non-	immune	 intestinal	 cells	 such	 as	 intestinal	 epithelial	 cells	
(IECs),	Goblet	cells,	Paneth	cells	and	 intestinal	 stem	cells	 (ISCs)	play	
important	roles	in	regulating	the	barrier	function	of	the	GI	tract	and	
the	 intestinal	microbiota	has	been	 shown	 to	promote	 the	 functions	

















Herein	we	will	 focus	 on	 the	 diet	 dependent	metabolites	which	 are	
generated	by	 the	breakdown	of	 the	host	nutrients	by	 the	 intestinal	
microbes.
3.1 | Short chain fatty acids
Anaerobic	 commensal	 bacteria	 such	 as	 Clostridia	 species	 produce	
short	chain	fatty	acids	 (SCFAs)	 from	fermentation	of	non-	digestible	
carbohydrates.10	SCFAs	are	 the	most	 studied	microbial	metabolites	
and	 include	 butyrate,	 acetate,	 and	 proprionate.	 They	 serve	 as	 an	




deprived	state	which	 led	 to	autophagy	whereby	 the	cells	degraded	
their	own	components	in	order	to	maintain	energy	homeostasis	and	
this	 was	 reversed	 by	 butyrate	 supplementation.11	 Besides	 provid-
ing	IECs	with	an	energy	source,	SCFAs	are	essential	for	maintaining	
the	 integrity	of	 the	 intestinal	mucosal	barrier	 through	 regulation	of	
functions	of	goblet	cells.12	The	barrier	 integrity	of	 IECs	was	further	
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(Figure	1).	 SCFAs	 such	 as	 butyrate	 play	 an	 integral	 part	 in	 innate	
immunity	 as	 they	 are	 histone	 deacetylase	 (HDAC)	 inhibitors	 that	
promote	 an	 anti-	inflammatory	 cell	 phenotype.	 GPCR43	 expression	
was	shown	to	be	necessary	 for	 the	effects	of	SCFAs	on	neutrophil	
chemotaxis.14	Other	studies	showed	that	SCFAs	inhibit	HDACs	and	




dependent	manner	which	 promoted	 epithelial	 repair	 and	mitigated	
the	 severity	 of	 inflammatory	 colitis.17	 Besides	 their	 involvement	 in	
innate	immune	responses,	SCFAs	were	shown	to	modulate	the	adap-




expression	 of	 anti-	inflammatory	 IL-	10	 producing	 Foxp3-	expressing	





Another	 group	 of	 microbial	 metabolites	 that	 regulate	 immunity	 in-
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signaling	is	controlled	by	the	intestinal	microbiota	through	two	main	
receptors:	the	nuclear	farnesoid	X	receptor	(FXR)	and	the	G	protein-	
coupled	 bile	 acid	 receptor	 1	 (GPBAR1)	 also	 known	 as	 TGR5.	Mice	
lacking	 FXR	 show	 compromised	 epithelial	 barrier	 function	 and	 en-
hanced	bacterial	translocation	from	the	intestine.20	Bile	acids	activate	















sis	 of	 anti-	inflammatory	 cytokines	 transforming	 growth	 factor-	beta	
(TGF-	β)	 and	 IL-	10.25	Moreover,	 oral	 administration	 of	 the	 probiotic	
bifidobacteria	 LKM512	 in	 combination	 with	 the	 amino	 acid	 argi-
nine,	which	 is	metabolized	 to	 produce	 polymaines,	 increased	 levels	
of	polyamines,	 improved	longevity,	and	protected	from	age-	induced	










Lactobacilli	utilizes	amino	acid	 tryptophan	 to	produce	AhR	 ligands	
such	as	 indole-	3-	aldehyde.28	AhR	 ligands	are	critical	 for	 the	main-
tenance	of	the	intestinal	epithelial	barrier.	Their	deficiency	in	mice	
results	 in	alterations	of	 the	 intestinal	microbiota	composition	with	
bacterial	 overgrowth,	 decrease	 in	 AMPs	 and	 intestinal	 epithelial	
lymphocytes	 (IELs),	 and	 reduced	 turnover	 of	 IECs.29	 AhR	 directly	
regulates	 innate	 immunity.	 It	 is	 necessary	 for	 expansion	 of	 IL-	22	
producing	 RORγt+	 ILC3s	 and	 the	 formation	 of	 ILFs,	 which	 were	
needed	for	the	clearance	of	Citrobacter rodentium	 infection.30	AhR	
effect	on	RORγt+	 ILC3s	can	be	 induced	by	dietary	 ligands	such	as	
those	 contained	 in	 vegetables	 of	 the	 family	 Brassicaceae.30	 They	
were	also	shown	to	be	important	in	adaptive	immunity.	A	reduction	
in	AhR	 ligands	 in	 response	 to	Cyp1a1	enzyme	activity	 in	 the	 IECs	
decreased	Th17	cells	and	impaired	Il-	22	production	in	response	to	
enteric	infections.31
4  | INTESTINAL MICROBIOTA AND ACUTE  
GVHD
A	healthy	intestinal	microbiota	is	diverse	and	dominated	by	obligate	
anaerobic	 bacteria.1	 During	 the	 process	 of	 allo-	HCT	 patients	 lose	




phylum	Frimicutes	 that	was	pronounced	 in	 those	 that	were	 treated	
with	antibiotics.32	Thus	the	process	of	allo-	HCT	has	been	shown	to	
alter	 the	 intestinal	microbiota	 composition	 and	 affect	 the	 intestinal	
homeostasis.
Reciprocally,	 the	 intestinal	microbiota	 has	 been	 shown	 to	mod-
ulate	 post	 allo-	HCT	 outcomes	 including	 acute	 GVHD.35-38	 Studies	
from	 the	1970s	 investigated	 the	 role	of	 the	 intestinal	mcirobiota	 in	
allo-	HCT	and	found	 less	acute	GVHD	in	mice	transplanted	 in	germ-	
free	 conditions	 or	 receiving	 gut	 decontamination	 antibiotics.4	 Some	
follow-	up	clinical	studies	showed	similar	beneficial	effects	of	bacterial	
decontamination	 in	allo-	HCT	patients	while	a	 few	others	did	not.39-
42	The	 reasons	 for	 these	disparate	 results	 remain	 unclear	 but	 could	
be	due	to	variation	in	success	of	decontamination	techniques	or	the	
specifics	of	the	alteration	 in	the	microbiota	composition	rather	than	
just	 a	 global	 loss	 of	 diversity.	 Recent	 studies	 show	 that	 changes	 in	
microbial	composition	post	allo-	HCT	were	more	pronounced	in	those	
that	 developed	 acute	 GVHD	 including	 greater	 loss	 of	 diversity,	 ex-
pansion	 of	 Enterobacteriales,	 Lactobacillales,	 Proteobacteria,	 and	
Akkermansia.43,44	 This	was	 accompanied	 by	 the	 loss	 of	 obligate	 an-
aerobic	bacteria	from	the	phylum	Firmicutes	(including	Clostridia	and	























of	PRRs	 in	acute	GVHD	has	been	covered	 in	other	 recent	 reviews.3 




5  | MICROBIAL METABOLITES AND 
ACUTE GVHD
The	 changes	 in	microbiome	 structure	 cause	 a	 change	 in	 intestinal	
metabolites.	A	recent	study	explored	the	role	of	microbial	metabo-
lites	 in	 acute	GVHD	 severity.45	 The	 study	 reported	data	 primarily	
on	 SCFAs	 and	 long	 chain	 fatty	 acids	 (LCFAs)	 from	 skin,	 intestine	
and	liver	post	experimental	allo-	HCT.	The	study	demonstrated	that	
amongst	 all	 the	 SCFAs	 and	 LCFAs	 from	various	 tissues	 and	 stool,	
only	the	SCFA	butyrate	was	significantly	decreased	only	in	the	IECs.	
The	impact	on	non	fatty	acid	metabolites	was	not	reported.	The	re-
duction	 in	 the	 IEC	 butyrate	was	 associated	with	 reduction	 in	 the	
microbial	diversity	and	 in	the	family	of	bacteria	that	are	known	to	
produce	butyrate	from	resistant	starch.	An	interesting	aspect	of	the	
study	was	 that	 the	diet	was	kept	 constant.	 It	 remains	unknown	 if	
changing	the	diet	to	resistant	starch,	the	fodder	for	bacterial	species	
that	break	it	down	to	butyrate,	might	alter	the	butyrate.	However,	
the	 study	 reported	 that	 supplementing	 the	 microbiome	 with	 17	
strains	of	clostridial	species	that	are	known	to	be	butyrate	produc-
ers	restored	butyrate	levels	in	both	antibiotic	treated	or	untreated	
recipients.	 Furthermore,	 the	 restoration	 of	 butyrate	 levels	 with	
exogenous	administration	of	butyrate	without	changing	the	micro-
biome	promoted	histone	acetylation	 in	 IECs	and	caused	enhanced	
expression	 of	 anti-	apoptotic	 proteins	 involved	 in	 barrier	 integrity	
such	as	JAM	and	occludin.	Importantly,	butyrate	administration	in-




strains	 of	 Clostridia,	 mitigated	 intestinal	 barrier	 damage,	 reduced	
acute	GVHD	specific	damage,	and	improved	survival	after	allo-	HCT.	





the	donor	Tregs	were	depleted	 from	 the	donor	 cells.	While	 these	
data	 suggest	protective	effects	on	acute	GVHD	could	occur	 inde-
pendent	 of	 donor	 Tregs,	 the	 study	 did	 not	 explore	 whether	 host	
Tregs	 played	 a	 role	 in	 acute	 GVHD	 protection.	 However,	 the	 re-
port	 suggests	 that	 direct	 effect	 of	 butyrate	 on	 IECs	might	 play	 a	
role	 in	 reducing	 acute	GVHD	 severity.	 This	 concept	 is	 now	being	
studied	in	two	clinical	trials	(www.clinicaltrials.gov:	NCT02763033,	





Currently	 there	 is	 paucity	 of	 data	 on	 other	 intestinal	 microbial	
metabolites	and	their	impact	in	acute	GVHD	(Table	1).	However,	one	







tions	 including,	but	not	 limited	 to,	whether	 it	 is	possible	 to	mitigate	
GI	damage	by	directly	affecting	target	cells	without	substantially	af-
fecting	the	immune	system.51	Do	other	SCFAs	a	role	or	is	this	unique	
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